Outpatient Cilta-cel for Relapsed/Refractory Multiple Myeloma

Taiga Nishihori, MD, senior member in the Blood & Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, discusses the findings from a single-center, retrospective study evaluating ciltacabtagene autoleucel (cilta-cel; Carvykti) given in the outpatient setting to patients with relapsed/refractory multiple myeloma, and the future directions for this research.

In this study, investigators evaluated patients with relapsed and/or refractory multiple myeloma who were hospitalized and treated commercial cilta-cel at Moffitt Cancer Center between May 2022 and May 2023. The specific focus of the study was to evaluate the first 30 days postinfusion.

According to Nishihori, cilta-cel in this setting appears safe and feasible when followed by the close monitoring of patients who are undergoing the chimeric antigen receptor (CAR) T-cell therapy. Specifically, the overall survival (OS) and progression-free survival (PFS) rates were similar across the administration types. The OS rate at 1 year for outpatient was 96.3% (95% CI, 76.5%-99.5%; P =.068). The PFS rate here was 85.8% (95% CI, 60.6%-95.5%; P =.10). Additionally, the median follow-up for surviving patients in the outpatient setting was 7.7 months (range, 2.9-14.4).

Transcription:

0:09 | We have shown that the duration of hospitalization is reduced. The survival rates and progression-free survival are similar between those patients who had mostly inpatient or outpatient inpatient vs entirely outpatient.

0:29 | Ciltacabtagene autoleucel or cilta-cel can be delivered on an outpatient model, which will expand a patient's ability to stay out of the hospital and have more time to relax while undergoing CAR T-cell therapy. We are attempting to expand this further to different products, and maybe in the future indications, we will have more patients going through outpatient CAR T.

REFERENCE:

Waqar S, Hansen DK, Freeman CL, et al. Evaluation of outpatient administration of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma: single center experience. Presented at: 2024 Transplantation & Cellular Therapy Meetings: February 21-24, 2024; San Antonio, TX. Abstract 532.